Clinical trials
Chronic Hepatitis clinical trials
Below are recruiting chronic hepatitis clinical trials, each written for real people, not researchers. We’re tracking 131 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07096193RecruitingPhase 1/Phase 2
Study of GS-4321 for chronic hepatitis delta
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
Anaheim, CaliforniaAges 18–69 - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT04896255Recruiting
Long-term follow-up of hepatitis B treatments
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
ShanghaiAges 18 years+ - NCT07487623Recruiting
Nutritional supplement for liver protection in hepatitis C
This trial tests whether a special nutritional supplement can protect the liver in people with chronic hepatitis C. If you have mild to moderate liver damage and meet the criteria, you may be able to join.
Guadalajara, JaliscoAges 18–69 - NCT07852091RecruitingPhase 2
Combination therapy aiming for a functional cure for chronic hepatitis B
This study tests a new combination of medicines to help your immune system control the hepatitis B virus, with the goal of stopping the need for long-term treatment. It may be an option for people who have taken or are currently taking hepatitis B medications.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07573943RecruitingPhase 4
ASC22 with Peg-IFN for chronic hepatitis B cure
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT05182463RecruitingPhase 4
Peginterferon test for inactive chronic hepatitis B
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
Guangzhou, GuangdongAges 18–60 - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07845058RecruitingPhase 2
Combination therapy for a functional cure of chronic hepatitis B
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07200908RecruitingPhase 3
Comparing brelovitug and bulevirtide for hepatitis delta
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
GrazAges 18–99 - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT05181826Recruiting
Blood collection study for cancer and benign diseases
This study collects blood samples from people with different health conditions (cancer, diabetes, liver disease, etc.) and from healthy volunteers. The goal is to find markers in the blood that could help detect or monitor diseases.
Redondo Beach, CaliforniaAges 18 years+ - NCT06696664Recruiting
Genetic study of chronic hepatitis B cure with long-acting interferon
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Beijing, Beijing MunicipalityAges 18–70 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07491848Recruiting
Mouth health study for hepatitis B and D patients
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
CraiovaAges 18 years+ - NCT07855029Recruiting
Quality of life after hepatitis B treatment outcomes
This study looks at how different outcomes of chronic hepatitis B treatment affect patients' quality of life. It includes people who have been functionally cured, those still on treatment, those who relapsed, and healthy controls to compare.
GuangzhouAges 18–65 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70
Hear when a new Chronic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis?
- Yes. Clin2 currently lists 131 recruiting chronic hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.